查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1576086

脂質低墮胎藥的全球市場的評估:各類型，各類藥物，各適應症，各給藥途徑，各流通管道，各地區，機會，預測(2017年～2031年)

Lipid-lowering Drugs Market Assessment, By Type, By Drug Class, By Indication, By Route of Administration, By Distribution Channel, By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 236 Pages | 商品交期: 3-5個工作天內

價格

全球降血脂藥物市場規模預計將從 2023 年的 303 億美元增至 2031 年的 384.7 億美元，預計 2024-2031 年的複合年增長率為 3.03%。由於心臟病患病率不斷上升、對早期診斷和適當治療方案的日益重視、醫療保健利益相關者對心臟健康和該領域投資的興趣以及監管政策的改進，預計該市場將以更快的速度增長預計會擴大。

降血脂藥物可降低血液膽固醇和三酸甘油酯，有助於預防心血管疾病，並控制血脂失調。它也被稱為血脂異常藥物或抗血脂藥物。久坐的生活方式、不健康的食物選擇和壓力引起的心血管疾病盛行率不斷上升，是此類藥物的主要市場需求。市場擴張的主要障礙是傳統藥物的使用與新治療方案的採用率之間的不匹配所造成的緊張。然而，新藥的監管批准預計將提供新的市場機會並促進市場成長。 2024年3月，Esperion Therapeutics, Inc.宣布其降血脂藥物NEXLETOL（bempedoic Acid）和NEXLIZET（bempedoic Acid，ezetimibe）的擴大適應症獲得美國FDA批准。這些批准允許用於降低患者心血管風險的一級和二級預防，無論是否使用他汀類藥物。這將使目標患者群體擴大到約 7,000 萬人，並將顯著推進非他汀類藥物 LDL-C 降低治療。

本報告提供全球脂質低墮胎藥市場相關調查分析，提供市場規模與預測，市場動態，主要企業的形勢等資訊。

目錄

第1章 計劃的範圍和定義

第2章 調查手法

第3章 摘要整理

第4章 全球脂質低墮胎藥市場預測(2017年～2031年)

  • 市場規模的分析與預測
    • 金額
  • 市場佔有率的分析與預測
    • 各類型
    • 各類藥物
    • 各適應症
    • 各給藥途徑
    • 各流通管道
    • 各地區
    • 市場佔有率分析:各企業(金額)(前五名公司和其他 - 2023年)
  • 市場地圖分析(2023年)
    • 各類型
    • 各類藥物
    • 各適應症
    • 各給藥途徑
    • 各流通管道
    • 各地區

第5章 北美的脂質低墮胎藥市場預測(2017年～2031年)

  • 市場規模的分析與預測
    • 金額
  • 市場佔有率的分析與預測
    • 各類型
    • 各類藥物
    • 各適應症
    • 各給藥途徑
    • 各流通管道
    • 佔有率:各國
  • 各國的市場評估
    • 美國的脂質低墮胎藥市場預測(2017年～2031年)
    • 加拿大
    • 墨西哥

第6章 歐洲的脂質低墮胎藥市場預測(2017年～2031年)

  • 德國
  • 法國
  • 義大利
  • 英國
  • 俄羅斯
  • 荷蘭
  • 西班牙
  • 波蘭

第7章 亞太地區的脂質低墮胎藥市場預測(2017年～2031年)

  • 印度
  • 中國
  • 日本
  • 澳洲
  • 越南
  • 韓國
  • 印尼
  • 菲律賓

第8章 南美的脂質低墮胎藥市場預測(2017年～2031年)

  • 巴西
  • 阿根廷

第9章 中東·非洲的脂質低墮胎藥市場預測(2017年～2031年)

  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非
  • 以色列

第10章 供需分析

第11章 價值鏈分析

第12章 波特的五力分析

第13章 大環境分析

第14章 價格分析

第15章 市場動態

  • 推動市場要素
  • 市場課題

第16章 市場趨勢與發展

第17章 法規結構和革新

  • 臨床試驗
  • 法規當局的認證

第18章 專利形勢

第19章 案例研究

第20章 競爭情形

  • 市場前五名領導者企業的競爭矩陣
  • 前五名公司的SWOT分析
  • 前十大主要企業的形勢
    • Amgen Inc.
    • Novartis AG
    • Dr. Reddy's Laboratories Limited
    • GlaxoSmithKline plc
    • Merck & Co., Inc.
    • Pfizer Inc.
    • Regeneron Pharmaceuticals, Inc.
    • Teva Pharmaceuticals Industries Ltd.
    • Sanofi S.A.
    • Sun Pharmaceutical Industries Ltd.

第21章 策略性推薦

第22章 本公司相關資料，免責聲明

Product Code: MX12133

Global lipid-lowering drugs market is projected to witness a CAGR of 3.03% during the forecast period 2024-2031, growing from USD 30.30 billion in 2023 to USD 38.47 billion in 2031. The market of lipid-lowering drugs is anticipated to expand at a faster pace owing to the rising prevalence of cardiac diseases, the growing emphasis on early diagnosis, and proper treatment regimens, coupled with healthcare stakeholders' attention towards heart health through investment in the field, and improved regulatory policies.

Lipid-lowering drugs help lower cholesterol and triglycerides in the blood, prevent cardiovascular diseases, and manage lipid disorders. They are also known as hyperlipidemia drugs or antihyperlipidemic drugs. The rising prevalence of cardiovascular diseases caused by sedentary lifestyles, unhealthy food choices, and stress is the primary market demand for such drugs. The primary hurdle for the expansion of this market is the tension between the widespread utilization of conventional drugs and novel treatment options owing to a mismatch in the adoption rate. However, the new drugs' regulatory approvals are expected to offer new market opportunities and enable market growth. In March 2024, Esperion Therapeutics, Inc. announced that the USFDA approved expanded labels for its lipid-lowering drugs, NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe). These approvals allow their use for cardiovascular risk reduction in primary and secondary prevention patients, regardless of statin use. It broadens the eligible patient population to approximately 70 million, significantly advancing in non-statin LDL-C lowering therapies.

High Cardiovascular Disease Burden to Boost Demand for Lipid-lowering Drugs

High lipid levels, especially high LDL cholesterol and triglycerides, trigger the development of cardiovascular diseases by promoting atherosclerosis. Hailed by increasing cases of cardiac diseases from lifestyles such as diet, sedentary lifestyle, and obesity, the need for lipid-lowering medications is profoundly greater than ever. Increasing prescriptions for statins and other lipid-modifying therapies to manage cholesterol and attenuate cardiovascular risk is expected to accelerate growth in the market for lipid-lowering drugs. Improvements in treatment options and personalized medicine further drive the ever-growing trend as healthcare providers seek more effective alternatives to combat the growing epidemic of rising lipid levels. For instance, according to an article published in Circulation Journal in June 2024, the prevalence of hypertension is projected to increase from 51.2% in 2020 to 61.0% in 2050. It is estimated that the prevalence of poor diet, inadequate physical activity, and smoking will improve over time, while inadequate sleep will worsen. Additionally, the prevalence of coronary disease, heart failure, stroke, atrial fibrillation, and total cardiovascular disease are expected to increase. Clinical cardiovascular diseases (CVD) are projected to affect 45 million adults, and CVD, including hypertension, will affect more than 184 million adults by 2050, which is more than 61% of the population.

Robust Drug Development Pipeline to Drive Market Growth

A strong drug development pipeline is one of the growth drivers in the market for lipid-lowering drugs. New research and results of clinical trials have led to the arrival of novel therapies answering different types of patient needs, such as genetic lipid disorders and intolerance to traditional statin therapy. Emerging classes of drugs, including PCSK9 inhibitors and other novel agents, provide efficient treatment alternatives. Personalization gets its stronghold in the ready availability of bespoke therapies, supported through genetic profiles, improving patient outcomes and compliance. The greater focus on preventive health care further helps add to the demand for effective solutions to manage lipids, ensuring a strong pipeline converts into significant market growth. For instance, in April 2024, Verve Therapeutics, Inc. announced updates on its PCSK9 program, highlighting the Heart-1 clinical trial of VERVE-101, which showed LDL-C reductions of up to 73%. However, the enrollment was paused due to safety concerns related to a participant. The company will prioritize VERVE-102, which uses a different delivery system and is set to enter the Heart-2 trial in Q2 2024, focusing on lipid-lowering treatments.

Statins and Combinations to Dominate the Lipid-lowering Drugs Market Share

The segment of statins and combinations holds the largest share of the lipid-lowering drugs market as they are proven to be effective and widely used, besides having significant clinical support. Atorvastatin and rosuvastatin are examples of effective statins that decrease the levels of LDL cholesterol and mean a substantial reduction in cardiovascular events. They have a long-proven record and are firmly embedded in preventive medicine. Also, the economic nature of generic statins supports their usability among healthcare providers and patients, enabling access to treatment for a larger population. Moreover, in the context of developing recognition of benefits beyond lipid-lowering, research is still ongoing on the anti-inflammatory properties of statins, making them more appealing. Therefore, with continuous improvement of the formulation and dosage of formulations, the segment of statins remains the core of lipid management by ensuring its dominance in the market for the foreseeable future. As per an article published in August 2024 in the Canadian Journal of Cardiology and several other literary sources, statins are proven to lower LDL-C levels ranging from 20%-60%, positioning them to be highly effective in the lipid-lowering drug category.

North America to Dominate the Lipid-lowering Drugs Market Share

The presence of several key factors, such as the high prevalence of cardiovascular diseases and obesity, leading North America to dominate the market for lipid-lowering drugs. The healthcare infrastructure is well established, with easy access to medical services that ensure timely diagnosis and treatment of hyperlipidemia. There is increased awareness of cardiovascular health among the population, leading to proactive screening and adherence to prescribed therapies. Major pharmaceutical companies in North America are fueling innovation by introducing new lipid-lowering medications. Additional factors favorable to the patient on lipid-lowering drugs are policies and insurance coverage for reimbursement. The regulatory initiatives from the USFDA further strengthen the market growth rate in the region. For instance, in March 2024, Regeneron Pharmaceuticals, Inc. announced that the USFDA extended the approval of Praluent (alirocumab) as an adjunct to diet and other low-density lipoprotein cholesterol (LDL-C) lowering therapies to include pediatric patients aged 8 and older with heterozygous familial hypercholesterolemia (HeFH).

Future Market Scenario (2024 - 2031F)

Recent advancements in the development of lipid-lowering drugs are changing the face of the cardiovascular market. Among these, emerging therapies targeting multiple pathways beyond the usual statins meet major needs in managing dyslipidemia. New molecules, like bempedoic acid and inclisiran, represent novel approaches. Bempedoic acid selectively inhibits cholesterol synthesis in the liver and makes it unable to synthesize cholesterol. In contrast, inclisiran is a siRNA that drastically lowers levels of LDL-C at very infrequent dosing. In addition, drugs targeting ANGPTL3 and ApoC-III for reduction in triglycerides and lipoprotein(a) may further change the management of patients resistant to treatments in use. All these developments are bound to impact market growth as they expand the array of treatments that are being put at the disposal of patients with a high cardiovascular risk profile. The new agents enhance the management of lipids and indicate atherosclerotic event reduction, therefore improving patient compliance and demand on the market.

Key Players Landscape and Outlook

The market players involved in manufacturing lipid-lowering drugs range from local generic drug producers to global pharmaceutical giants fragmenting the market. However, there are many market players, branded drugs, such as Repatha from Amgen Inc., attract a significant market share in terms of revenue. Recent activities in the market include regulatory initiatives, manufacturing collaborations, and acquisitions.

In October 2024, AstraZeneca announced an exclusive license agreement with CSPC Pharmaceutical Group Ltd to fasten the development of YS2302018, a novel lipid-lowering asset targeting lipoprotein(a) CSPC. This collaboration aims to develop therapies that can significantly reduce cardiovascular disease risk associated with elevated lipoprotein(a) levels. The agreement underscores AstraZeneca's commitment to advancing innovative treatments in cardiovascular health, potentially enhancing its portfolio in lipid management.

In May 2024, Click Therapeutics, Inc. announced its expansion into obesity and cardiometabolic diseases through the acquisition of Better Therapeutics, Inc.'s assets, including the FDA-authorized AspyreRx for type 2 diabetes, and the development of candidates, such as BT-002, BT-003, and BT-004, for hyperlipidemia and metabolic dysfunction-associated steatohepatitis (MASH). The focus will be on developing AspyreRx for obesity treatment and optimizing it alongside anti-obesity medications. This initiative aims to enhance patient outcomes and leverage AI-enabled platforms for personalized care in chronic weight management and related conditions.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Global Lipid-lowering Drugs Market Outlook, 2017-2031F

  • 4.1. Market Size Analysis & Forecast
    • 4.1.1. By Value
  • 4.2. Market Share Analysis & Forecast
    • 4.2.1. By Type
      • 4.2.1.1. Branded
      • 4.2.1.2. Generic
    • 4.2.2. By Drug Class
      • 4.2.2.1. Statins and Combinations
      • 4.2.2.2. Bile Acid Sequestrants
      • 4.2.2.3. Cholesterol Absorption Inhibitors
      • 4.2.2.4. Fibric Acid Derivatives
      • 4.2.2.5. PCSK9 Inhibitors
      • 4.2.2.6. Other Drug Classes
    • 4.2.3. By Indication
      • 4.2.3.1. Hypercholesterolemia
      • 4.2.3.2. Coronary Artery Disease
      • 4.2.3.3. High Triglycerides
    • 4.2.4. By Route of Administration
      • 4.2.4.1. Oral
      • 4.2.4.2. Parenteral
    • 4.2.5. By Distribution Channel
      • 4.2.5.1. Hospital Pharmacies
      • 4.2.5.2. Retail Pharmacies
      • 4.2.5.3. Online Pharmacies
      • 4.2.5.4. Others
    • 4.2.6. By Region
      • 4.2.6.1. North America
      • 4.2.6.2. Europe
      • 4.2.6.3. Asia-Pacific
      • 4.2.6.4. South America
      • 4.2.6.5. Middle East and Africa
    • 4.2.7. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2023)
  • 4.3. Market Map Analysis, 2023
    • 4.3.1. By Type
    • 4.3.2. By Drug Class
    • 4.3.3. By Indication
    • 4.3.4. By Route of Administration
    • 4.3.5. By Distribution Channel
    • 4.3.6. By Region

5. North America Lipid-lowering Drugs Market Outlook, 2017-2031F*

  • 5.1. Market Size Analysis & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share Analysis & Forecast
    • 5.2.1. By Type
      • 5.2.1.1. Branded
      • 5.2.1.2. Generic
    • 5.2.2. By Drug Class
      • 5.2.2.1. Statins and Combinations
      • 5.2.2.2. Bile Acid Sequestrants
      • 5.2.2.3. Cholesterol Absorption Inhibitors
      • 5.2.2.4. Fibric Acid Derivatives
      • 5.2.2.5. PCSK9 Inhibitors
      • 5.2.2.6. Other Drug Classes
    • 5.2.3. By Indication
      • 5.2.3.1. Hypercholesterolemia
      • 5.2.3.2. Coronary Artery Disease
      • 5.2.3.3. High Triglycerides
    • 5.2.4. By Route of Administration
      • 5.2.4.1. Oral
      • 5.2.4.2. Parenteral
    • 5.2.5. By Distribution Channel
      • 5.2.5.1. Hospital Pharmacies
      • 5.2.5.2. Retail Pharmacies
      • 5.2.5.3. Online Pharmacies
      • 5.2.5.4. Others
    • 5.2.6. By Country Share
      • 5.2.6.1. United States
      • 5.2.6.2. Canada
      • 5.2.6.3. Mexico
  • 5.3. Country Market Assessment
    • 5.3.1. United States Lipid-lowering Drugs Market Outlook, 2017-2031F*
      • 5.3.1.1. Market Size Analysis & Forecast
        • 5.3.1.1.1. By Value
      • 5.3.1.2. Market Share Analysis & Forecast
        • 5.3.1.2.1. By Type
          • 5.3.1.2.1.1. Branded
          • 5.3.1.2.1.2. Generic
        • 5.3.1.2.2. By Drug Class
          • 5.3.1.2.2.1. Statins and Combinations
          • 5.3.1.2.2.2. Bile Acid Sequestrants
          • 5.3.1.2.2.3. Cholesterol Absorption Inhibitors
          • 5.3.1.2.2.4. Fibric Acid Derivatives
          • 5.3.1.2.2.5. PCSK9 Inhibitors
          • 5.3.1.2.2.6. Other Drug Classes
        • 5.3.1.2.3. By Indication
          • 5.3.1.2.3.1. Hypercholesterolemia
          • 5.3.1.2.3.2. Coronary Artery Disease
          • 5.3.1.2.3.3. High Triglycerides
        • 5.3.1.2.4. By Route of Administration
          • 5.3.1.2.4.1. Oral
          • 5.3.1.2.4.2. Parenteral
        • 5.3.1.2.5. By Distribution Channel
          • 5.3.1.2.5.1. Hospital Pharmacies
          • 5.3.1.2.5.2. Retail Pharmacies
          • 5.3.1.2.5.3. Online Pharmacies
          • 5.3.1.2.5.4. Others
    • 5.3.2. Canada
    • 5.3.3. Mexico

All segments will be provided for all regions and countries covered

6. Europe Lipid-lowering Drugs Market Outlook, 2017-2031F

  • 6.1. Germany
  • 6.2. France
  • 6.3. Italy
  • 6.4. United Kingdom
  • 6.5. Russia
  • 6.6. Netherlands
  • 6.7. Spain
  • 6.8. Poland

7. Asia-Pacific Lipid-lowering Drugs Market Outlook, 2017-2031F

  • 7.1. India
  • 7.2. China
  • 7.3. Japan
  • 7.4. Australia
  • 7.5. Vietnam
  • 7.6. South Korea
  • 7.7. Indonesia
  • 7.8. Philippines

8. South America Lipid-lowering Drugs Market Outlook, 2017-2031F

  • 8.1. Brazil
  • 8.2. Argentina

9. Middle East and Africa Lipid-lowering Drugs Market Outlook, 2017-2031F

  • 9.1. Saudi Arabia
  • 9.2. UAE
  • 9.3. South Africa
  • 9.4. Israel

10. Demand Supply Analysis

11. Value Chain Analysis

12. Porter's Five Forces Analysis

13. PESTLE Analysis

14. Pricing Analysis

15. Market Dynamics

  • 15.1. Market Drivers
  • 15.2. Market Challenges

16. Market Trends and Developments

17. Regulatory Framework and Innovation

  • 17.1. Clinical Trials
  • 17.2. Regulatory Approvals

18. Patent Landscape

19. Case Studies

20. Competitive Landscape

  • 20.1. Competition Matrix of Top 5 Market Leaders
  • 20.2. SWOT Analysis for Top 5 Players
  • 20.3. Key Players Landscape for Top 10 Market Players
    • 20.3.1. Amgen Inc.
      • 20.3.1.1. Company Details
      • 20.3.1.2. Key Management Personnel
      • 20.3.1.3. Products and Services
      • 20.3.1.4. Financials (As Reported)
      • 20.3.1.5. Key Market Focus and Geographical Presence
      • 20.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
    • 20.3.2. Novartis AG
    • 20.3.3. Dr. Reddy's Laboratories Limited
    • 20.3.4. GlaxoSmithKline plc
    • 20.3.5. Merck & Co., Inc.
    • 20.3.6. Pfizer Inc.
    • 20.3.7. Regeneron Pharmaceuticals, Inc.
    • 20.3.8. Teva Pharmaceuticals Industries Ltd.
    • 20.3.9. Sanofi S.A.
    • 20.3.10. Sun Pharmaceutical Industries Ltd.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

21. Strategic Recommendations

22. About Us and Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Lipid-lowering Drugs Market, By Value, In USD Billion, 2017-2031F
  • Figure 2. Global Lipid-lowering Drugs Market Share (%), By Type, 2017-2031F
  • Figure 3. Global Lipid-lowering Drugs Market Share (%), By Drug Class, 2017-2031F
  • Figure 4. Global Lipid-lowering Drugs Market Share (%), By Indication, 2017-2031F
  • Figure 5. Global Lipid-lowering Drugs Market Share (%), By Route of Administration, 2017-2031F
  • Figure 6. Global Lipid-lowering Drugs Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 7. Global Lipid-lowering Drugs Market Share (%), By Region, 2017-2031F
  • Figure 8. North America Lipid-lowering Drugs Market, By Value, In USD Billion, 2017-2031F
  • Figure 9. North America Lipid-lowering Drugs Market Share (%), By Type, 2017-2031F
  • Figure 10. North America Lipid-lowering Drugs Market Share (%), By Drug Class, 2017-2031F
  • Figure 11. North America Lipid-lowering Drugs Market Share (%), By Indication, 2017-2031F
  • Figure 12. North America Lipid-lowering Drugs Market Share (%), By Route of Administration, 2017-2031F
  • Figure 13. North America Lipid-lowering Drugs Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 14. North America Lipid-lowering Drugs Market Share (%), By Country, 2017-2031F
  • Figure 15. United States Lipid-lowering Drugs Market, By Value, In USD Billion, 2017-2031F
  • Figure 16. United States Lipid-lowering Drugs Market Share (%), By Type, 2017-2031F
  • Figure 17. United States Lipid-lowering Drugs Market Share (%), By Drug Class, 2017-2031F
  • Figure 18. United States Lipid-lowering Drugs Market Share (%), By Indication, 2017-2031F
  • Figure 19. United States Lipid-lowering Drugs Market Share (%), By Route of Administration, 2017-2031F
  • Figure 20. United States Lipid-lowering Drugs Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 21. Canada Lipid-lowering Drugs Market, By Value, In USD Billion, 2017-2031F
  • Figure 22. Canada Lipid-lowering Drugs Market Share (%), By Type, 2017-2031F
  • Figure 23. Canada Lipid-lowering Drugs Market Share (%), By Drug Class, 2017-2031F
  • Figure 24. Canada Lipid-lowering Drugs Market Share (%), By Indication, 2017-2031F
  • Figure 25. Canada Lipid-lowering Drugs Market Share (%), By Route of Administration, 2017-2031F
  • Figure 26. Canada Lipid-lowering Drugs Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 27. Mexico Lipid-lowering Drugs Market, By Value, In USD Billion, 2017-2031F
  • Figure 28. Mexico Lipid-lowering Drugs Market Share (%), By Type, 2017-2031F
  • Figure 29. Mexico Lipid-lowering Drugs Market Share (%), By Drug Class, 2017-2031F
  • Figure 30. Mexico Lipid-lowering Drugs Market Share (%), By Indication, 2017-2031F
  • Figure 31. Mexico Lipid-lowering Drugs Market Share (%), By Route of Administration, 2017-2031F
  • Figure 32. Mexico Lipid-lowering Drugs Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 33. Europe Lipid-lowering Drugs Market, By Value, In USD Billion, 2017-2031F
  • Figure 34. Europe Lipid-lowering Drugs Market Share (%), By Type, 2017-2031F
  • Figure 35. Europe Lipid-lowering Drugs Market Share (%), By Drug Class, 2017-2031F
  • Figure 36. Europe Lipid-lowering Drugs Market Share (%), By Indication, 2017-2031F
  • Figure 37. Europe Lipid-lowering Drugs Market Share (%), By Route of Administration, 2017-2031F
  • Figure 38. Europe Lipid-lowering Drugs Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 39. Europe Lipid-lowering Drugs Market Share (%), By Country, 2017-2031F
  • Figure 40. Germany Lipid-lowering Drugs Market, By Value, In USD Billion, 2017-2031F
  • Figure 41. Germany Lipid-lowering Drugs Market Share (%), By Type, 2017-2031F
  • Figure 42. Germany Lipid-lowering Drugs Market Share (%), By Drug Class, 2017-2031F
  • Figure 43. Germany Lipid-lowering Drugs Market Share (%), By Indication, 2017-2031F
  • Figure 44. Germany Lipid-lowering Drugs Market Share (%), By Route of Administration, 2017-2031F
  • Figure 45. Germany Lipid-lowering Drugs Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 46. France Lipid-lowering Drugs Market, By Value, In USD Billion, 2017-2031F
  • Figure 47. France Lipid-lowering Drugs Market Share (%), By Type, 2017-2031F
  • Figure 48. France Lipid-lowering Drugs Market Share (%), By Drug Class, 2017-2031F
  • Figure 49. France Lipid-lowering Drugs Market Share (%), By Indication, 2017-2031F
  • Figure 50. France Lipid-lowering Drugs Market Share (%), By Route of Administration, 2017-2031F
  • Figure 51. France Lipid-lowering Drugs Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 52. Italy Lipid-lowering Drugs Market, By Value, In USD Billion, 2017-2031F
  • Figure 53. Italy Lipid-lowering Drugs Market Share (%), By Type, 2017-2031F
  • Figure 54. Italy Lipid-lowering Drugs Market Share (%), By Drug Class, 2017-2031F
  • Figure 55. Italy Lipid-lowering Drugs Market Share (%), By Indication, 2017-2031F
  • Figure 56. Italy Lipid-lowering Drugs Market Share (%), By Route of Administration, 2017-2031F
  • Figure 57. Italy Lipid-lowering Drugs Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 58. United Kingdom Lipid-lowering Drugs Market, By Value, In USD Billion, 2017-2031F
  • Figure 59. United Kingdom Lipid-lowering Drugs Market Share (%), By Type, 2017-2031F
  • Figure 60. United Kingdom Lipid-lowering Drugs Market Share (%), By Drug Class, 2017-2031F
  • Figure 61. United Kingdom Lipid-lowering Drugs Market Share (%), By Indication, 2017-2031F
  • Figure 62. United Kingdom Lipid-lowering Drugs Market Share (%), By Route of Administration, 2017-2031F
  • Figure 63. United Kingdom Lipid-lowering Drugs Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 64. Russia Lipid-lowering Drugs Market, By Value, In USD Billion, 2017-2031F
  • Figure 65. Russia Lipid-lowering Drugs Market Share (%), By Type, 2017-2031F
  • Figure 66. Russia Lipid-lowering Drugs Market Share (%), By Drug Class, 2017-2031F
  • Figure 67. Russia Lipid-lowering Drugs Market Share (%), By Indication, 2017-2031F
  • Figure 68. Russia Lipid-lowering Drugs Market Share (%), By Route of Administration, 2017-2031F
  • Figure 69. Russia Lipid-lowering Drugs Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 70. Netherlands Lipid-lowering Drugs Market, By Value, In USD Billion, 2017-2031F
  • Figure 71. Netherlands Lipid-lowering Drugs Market Share (%), By Type, 2017-2031F
  • Figure 72. Netherlands Lipid-lowering Drugs Market Share (%), By Drug Class, 2017-2031F
  • Figure 73. Netherlands Lipid-lowering Drugs Market Share (%), By Indication, 2017-2031F
  • Figure 74. Netherlands Lipid-lowering Drugs Market Share (%), By Route of Administration, 2017-2031F
  • Figure 75. Netherlands Lipid-lowering Drugs Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 76. Spain Lipid-lowering Drugs Market, By Value, In USD Billion, 2017-2031F
  • Figure 77. Spain Lipid-lowering Drugs Market Share (%), By Type, 2017-2031F
  • Figure 78. Spain Lipid-lowering Drugs Market Share (%), By Drug Class, 2017-2031F
  • Figure 79. Spain Lipid-lowering Drugs Market Share (%), By Indication, 2017-2031F
  • Figure 80. Spain Lipid-lowering Drugs Market Share (%), By Route of Administration, 2017-2031F
  • Figure 81. Spain Lipid-lowering Drugs Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 82. Turkey Lipid-lowering Drugs Market, By Value, In USD Billion, 2017-2031F
  • Figure 83. Turkey Lipid-lowering Drugs Market Share (%), By Type, 2017-2031F
  • Figure 84. Turkey Lipid-lowering Drugs Market Share (%), By Drug Class, 2017-2031F
  • Figure 85. Turkey Lipid-lowering Drugs Market Share (%), By Indication, 2017-2031F
  • Figure 86. Turkey Lipid-lowering Drugs Market Share (%), By Route of Administration, 2017-2031F
  • Figure 87. Turkey Lipid-lowering Drugs Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 88. Poland Lipid-lowering Drugs Market, By Value, In USD Billion, 2017-2031F
  • Figure 89. Poland Lipid-lowering Drugs Market Share (%), By Type, 2017-2031F
  • Figure 90. Poland Lipid-lowering Drugs Market Share (%), By Drug Class, 2017-2031F
  • Figure 91. Poland Lipid-lowering Drugs Market Share (%), By Indication, 2017-2031F
  • Figure 92. Poland Lipid-lowering Drugs Market Share (%), By Route of Administration, 2017-2031F
  • Figure 93. Poland Lipid-lowering Drugs Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 94. South America Lipid-lowering Drugs Market, By Value, In USD Billion, 2017-2031F
  • Figure 95. South America Lipid-lowering Drugs Market Share (%), By Type, 2017-2031F
  • Figure 96. South America Lipid-lowering Drugs Market Share (%), By Drug Class, 2017-2031F
  • Figure 97. South America Lipid-lowering Drugs Market Share (%), By Indication, 2017-2031F
  • Figure 98. South America Lipid-lowering Drugs Market Share (%), By Route of Administration, 2017-2031F
  • Figure 99. South America Lipid-lowering Drugs Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 100. South America Lipid-lowering Drugs Market Share (%), By Country, 2017-2031F
  • Figure 101. Brazil Lipid-lowering Drugs Market, By Value, In USD Billion, 2017-2031F
  • Figure 102. Brazil Lipid-lowering Drugs Market Share (%), By Type, 2017-2031F
  • Figure 103. Brazil Lipid-lowering Drugs Market Share (%), By Drug Class, 2017-2031F
  • Figure 104. Brazil Lipid-lowering Drugs Market Share (%), By Indication, 2017-2031F
  • Figure 105. Brazil Lipid-lowering Drugs Market Share (%), By Route of Administration, 2017-2031F
  • Figure 106. Brazil Lipid-lowering Drugs Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 107. Argentina Lipid-lowering Drugs Market, By Value, In USD Billion, 2017-2031F
  • Figure 108. Argentina Lipid-lowering Drugs Market Share (%), By Type, 2017-2031F
  • Figure 109. Argentina Lipid-lowering Drugs Market Share (%), By Drug Class, 2017-2031F
  • Figure 110. Argentina Lipid-lowering Drugs Market Share (%), By Indication, 2017-2031F
  • Figure 111. Argentina Lipid-lowering Drugs Market Share (%), By Route of Administration, 2017-2031F
  • Figure 112. Argentina Lipid-lowering Drugs Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 113. Asia-Pacific Lipid-lowering Drugs Market, By Value, In USD Billion, 2017-2031F
  • Figure 114. Asia-Pacific Lipid-lowering Drugs Market Share (%), By Type, 2017-2031F
  • Figure 115. Asia-Pacific Lipid-lowering Drugs Market Share (%), By Drug Class, 2017-2031F
  • Figure 116. Asia-Pacific Lipid-lowering Drugs Market Share (%), By Indication, 2017-2031F
  • Figure 117. Asia-Pacific Lipid-lowering Drugs Market Share (%), By Route of Administration, 2017-2031F
  • Figure 118. Asia-Pacific Lipid-lowering Drugs Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 119. Asia-Pacific Lipid-lowering Drugs Market Share (%), By Country, 2017-2031F
  • Figure 120. India Lipid-lowering Drugs Market, By Value, In USD Billion, 2017-2031F
  • Figure 121. India Lipid-lowering Drugs Market Share (%), By Type, 2017-2031F
  • Figure 122. India Lipid-lowering Drugs Market Share (%), By Drug Class, 2017-2031F
  • Figure 123. India Lipid-lowering Drugs Market Share (%), By Indication, 2017-2031F
  • Figure 124. India Lipid-lowering Drugs Market Share (%), By Route of Administration, 2017-2031F
  • Figure 125. India Lipid-lowering Drugs Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 126. China Lipid-lowering Drugs Market, By Value, In USD Billion, 2017-2031F
  • Figure 127. China Lipid-lowering Drugs Market Share (%), By Type, 2017-2031F
  • Figure 128. China Lipid-lowering Drugs Market Share (%), By Drug Class, 2017-2031F
  • Figure 129. China Lipid-lowering Drugs Market Share (%), By Indication, 2017-2031F
  • Figure 130. China Lipid-lowering Drugs Market Share (%), By Route of Administration, 2017-2031F
  • Figure 131. China Lipid-lowering Drugs Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 132. Japan Lipid-lowering Drugs Market, By Value, In USD Billion, 2017-2031F
  • Figure 133. Japan Lipid-lowering Drugs Market Share (%), By Type, 2017-2031F
  • Figure 134. Japan Lipid-lowering Drugs Market Share (%), By Drug Class, 2017-2031F
  • Figure 135. Japan Lipid-lowering Drugs Market Share (%), By Indication, 2017-2031F
  • Figure 136. Japan Lipid-lowering Drugs Market Share (%), By Route of Administration, 2017-2031F
  • Figure 137. Japan Lipid-lowering Drugs Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 138. Australia Lipid-lowering Drugs Market, By Value, In USD Billion, 2017-2031F
  • Figure 139. Australia Lipid-lowering Drugs Market Share (%), By Type, 2017-2031F
  • Figure 140. Australia Lipid-lowering Drugs Market Share (%), By Drug Class, 2017-2031F
  • Figure 141. Australia Lipid-lowering Drugs Market Share (%), By Indication, 2017-2031F
  • Figure 142. Australia Lipid-lowering Drugs Market Share (%), By Route of Administration, 2017-2031F
  • Figure 143. Australia Lipid-lowering Drugs Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 144. Vietnam Lipid-lowering Drugs Market, By Value, In USD Billion, 2017-2031F
  • Figure 145. Vietnam Lipid-lowering Drugs Market Share (%), By Type, 2017-2031F
  • Figure 146. Vietnam Lipid-lowering Drugs Market Share (%), By Drug Class, 2017-2031F
  • Figure 147. Vietnam Lipid-lowering Drugs Market Share (%), By Indication, 2017-2031F
  • Figure 148. Vietnam Lipid-lowering Drugs Market Share (%), By Route of Administration, 2017-2031F
  • Figure 149. Vietnam Lipid-lowering Drugs Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 150. South Korea Lipid-lowering Drugs Market, By Value, In USD Billion, 2017-2031F
  • Figure 151. South Korea Lipid-lowering Drugs Market Share (%), By Type, 2017-2031F
  • Figure 152. South Korea Lipid-lowering Drugs Market Share (%), By Drug Class, 2017-2031F
  • Figure 153. South Korea Lipid-lowering Drugs Market Share (%), By Indication, 2017-2031F
  • Figure 154. South Korea Lipid-lowering Drugs Market Share (%), By Route of Administration, 2017-2031F
  • Figure 155. South Korea Lipid-lowering Drugs Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 156. Indonesia Lipid-lowering Drugs Market, By Value, In USD Billion, 2017-2031F
  • Figure 157. Indonesia Lipid-lowering Drugs Market Share (%), By Type, 2017-2031F
  • Figure 158. Indonesia Lipid-lowering Drugs Market Share (%), By Drug Class, 2017-2031F
  • Figure 159. Indonesia Lipid-lowering Drugs Market Share (%), By Indication, 2017-2031F
  • Figure 160. Indonesia Lipid-lowering Drugs Market Share (%), By Route of Administration, 2017-2031F
  • Figure 161. Indonesia Lipid-lowering Drugs Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 162. Philippines Lipid-lowering Drugs Market, By Value, In USD Billion, 2017-2031F
  • Figure 163. Philippines Lipid-lowering Drugs Market Share (%), By Type, 2017-2031F
  • Figure 164. Philippines Lipid-lowering Drugs Market Share (%), By Drug Class, 2017-2031F
  • Figure 165. Philippines Lipid-lowering Drugs Market Share (%), By Indication, 2017-2031F
  • Figure 166. Philippines Lipid-lowering Drugs Market Share (%), By Route of Administration, 2017-2031F
  • Figure 167. Philippines Lipid-lowering Drugs Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 168. Middle East & Africa Lipid-lowering Drugs Market, By Value, In USD Billion, 2017-2031F
  • Figure 169. Middle East & Africa Lipid-lowering Drugs Market Share (%), By Type, 2017-2031F
  • Figure 170. Middle East & Africa Lipid-lowering Drugs Market Share (%), By Drug Class, 2017-2031F
  • Figure 171. Middle East & Africa Lipid-lowering Drugs Market Share (%), By Indication, 2017-2031F
  • Figure 172. Middle East & Africa Lipid-lowering Drugs Market Share (%), By Route of Administration, 2017-2031F
  • Figure 173. Middle East & Africa Lipid-lowering Drugs Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 174. Middle East & Africa Lipid-lowering Drugs Market Share (%), By Country, 2017-2031F
  • Figure 175. Saudi Arabia Lipid-lowering Drugs Market, By Value, In USD Billion, 2017-2031F
  • Figure 176. Saudi Arabia Lipid-lowering Drugs Market Share (%), By Type, 2017-2031F
  • Figure 177. Saudi Arabia Lipid-lowering Drugs Market Share (%), By Drug Class, 2017-2031F
  • Figure 178. Saudi Arabia Lipid-lowering Drugs Market Share (%), By Indication, 2017-2031F
  • Figure 179. Saudi Arabia Lipid-lowering Drugs Market Share (%), By Route of Administration, 2017-2031F
  • Figure 180. Saudi Arabia Lipid-lowering Drugs Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 181. UAE Lipid-lowering Drugs Market, By Value, In USD Billion, 2017-2031F
  • Figure 182. UAE Lipid-lowering Drugs Market Share (%), By Type, 2017-2031F
  • Figure 183. UAE Lipid-lowering Drugs Market Share (%), By Drug Class, 2017-2031F
  • Figure 184. UAE Lipid-lowering Drugs Market Share (%), By Indication, 2017-2031F
  • Figure 185. UAE Lipid-lowering Drugs Market Share (%), By Route of Administration, 2017-2031F
  • Figure 186. UAE Lipid-lowering Drugs Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 187. South Africa Lipid-lowering Drugs Market, By Value, In USD Billion, 2017-2031F
  • Figure 188. South Africa Lipid-lowering Drugs Market Share (%), By Type, 2017-2031F
  • Figure 189. South Africa Lipid-lowering Drugs Market Share (%), By Drug Class, 2017-2031F
  • Figure 190. South Africa Lipid-lowering Drugs Market Share (%), By Indication, 2017-2031F
  • Figure 191. South Africa Lipid-lowering Drugs Market Share (%), By Route of Administration, 2017-2031F
  • Figure 192. South Africa Lipid-lowering Drugs Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 193. By Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 194. By Drug Class Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 195. By Indication Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 196. By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 197. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 198. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023